TRI and MCC Integrate RBM Tools
The solution will ‘hand-hold’ companies through the process of performing a protocol risk assessment and developing resulting quality risk management plan.
Following a long-standing working relationship between Triumph Research Intelligence (TRI) and the Metrics Champion Consortium (MCC), TRI will make MCC’s Risk Assessment and Mitigation Management Tool (RAMMT) available as part of the risk assessment and management module in its OPRA Risk-Based Monitoring and Quality Management platform. The OPRA solution will ‘hand-hold’ companies through the process of performing a protocol risk assessment and developing resulting quality risk management plan in a centrally accessible, cloud based application, and provide the guidance which comes from the MCC’s RAMMT content at the same time.
Read the full release.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
